刘锦锋

刘锦锋,博士,研究生导师、副主任医师。2000~2011年在西安交通大学学习,并获得博士学位。2009-2011在美国印第安纳大学作为联合培养博士学习。从事感染病临床、科研和教学,承担国家自然科学基金(主持)2项,参与国家自然科学基金6项,主持省市级科研基金多项,参与科技部“十一五”“十二五”“十三五”重大传染病专项研究,发表第一作者/通讯作者SCI 文章10余篇,获陕西省科技进步奖二等奖1项(第2)。作为主要参与者制定我国首部基于循证医学证据的乙肝传播阻断指南《中国乙型肝炎病毒母婴传播防治指南(2019年版)》。

研究领域(方向)

1.乙肝母婴阻断;

2. HCC发生机制研究

3. 肝损害的免疫机制

科研项目

主持国家自然科学基金2项,参与国家自然科学基金5项,参与国家“十一五”、“十二五”、“十三五”重大传染病专项:

1.国家自然科学基金面上项目,81670537、IL-6对NTCP介导HBV胎盘细胞感染及细胞间直接感染的调节、2017/1-2020/12、50万、在研、主持

2.国家自然科学基金青年项目,31100129、hRIP对HIV-1病毒基因的转录后调节、2012/01-2014/12、23万元、结题、主持

3.国家自然科学基金面上项目,81770594,细胞与线粒体自噬和滋养细胞损伤及其与HBV感染宫内传播的关系研究、2018/1-2021/12、54万、在研、参与

4.国家自然科学基金面上项目,81770594,细胞与线粒体自噬和滋养细胞损伤及其与HBV感染宫内传播的关系研究、2018/1-2021/12、54万、在研、参与

5.国家自然科学基金面上项目,81570528,磷酸化Atg13介导的线粒体自噬在肝星状细胞活化中的机制、2018/1-2021/12、62万、在研、参与

6.科技重大专项“十三五”课题,2017ZX10001-002、提高HBeAg阳性慢性乙型肝炎患者HBsAg阴转率抗病毒/免疫治疗新方案的研究、2017/1-2021/12、86万、在研、参与

7.科技重大专项“十二五”课题,2012ZX10002-007、病毒性肝炎转归预警机制的研究、2012/1-2016/12、180万、在研、参与

8.科技重大专项“十一五”课题,2008ZX10002-007、病毒性肝炎转归预警机制的研究、2008/1-2012/12、160万、结题、参与

9.国家自然科学基金,30872219、不良结局家族聚集性HBV感染NK细胞功能缺陷研究、2009/1-2011/12、35万、结题、参与

10.国家自然科学基金,30700712、不良结局家族聚集性HBV感染宿主因素研究、2008/1-2010/12、17万、结题、参与

11.国家自然科学基金,30671862,HBV前X基因致癌作用的体内外研究、2007/1-2009/12,30万、结题、参与

*学术集科研成果、专利、论文发表的第一作者及通讯作者SCI文章:

不良结局家族聚集性HBV感染的基础与临床研究,陕西省科学技术二等奖(2018 R2

5年发表的第一作者/通讯作者SCI文章:

1.Liu Jinfeng,Chen, T., Chen, Y., Ren, H., Wang, G., Zhang, W., Zhao, Y., Society of Infectious, D., Chinese Medical, A., 2020. 2019 Chinese Clinical Practice Guidelines for the Prevention of Mother-to-child Transmission of Hepatitis B Virus. J Clin Transl Hepatol 8, 397-406.

2. . Wu Y,Liu Jinfeng(共一), Feng Y, Fu S, Ji F, Ge L, Yao N, Luo X, Zhao Y, Chen Y, Yang Y, & Chen T (2020) Efficacy and safety of antiviral therapy for HBV in different trimesters of pregnancy: systematic review and network meta-analysis.Hepatol Int.

3. Wang J, Hu C, Chen Y, Liu Z, Yu Q, Yang S, Dong J, Yang Y, Wu Y, Ren D, Yao N, Guo D, Tian Z, Zhao Y, Chen T, He Y, &Liu Jinfeng(2019) HBV reactivation during direct-acting antiviral therapy in hepatitis B and C coinfected patients undergoing haemodialysis.Antiviral therapy24(2):77-84.

4.Liu Jinfeng, Wang J, Yan T, Du D, Qi C, Cao F, Yao N, Yang Y, He Y, Tian Z, Ren D, Zhu L, Chen T, & Zhao Y (2019) Efficacy and safety of telbivudine and tenofovir disoproxil fumarate in preventing hepatitis B vertical transmission: A real-life practice.J Viral Hepat26(10):1170-1177.

5. Chen T,Liu Jinfeng(共一), Yu Q, Yao N, Yang Y, Wu Y, Ren D, Tian Z, Zhao Y, & Wang J (2019) Tenofovir plus hepatitis B immunoglobulin treatment resulted in a rapid HBV DNA load decline in high-risk pregnant women who missed the optimal time window of antiviral prophylaxis.Antiviral therapy24(2):125-131.

6.Liu Jinfeng, Wang J, Qi C, Cao F, Tian Z, Guo D, Yan T, Li Q, Yang S, Fu J, Tang X, Kou X, Liu N, Jiang Z, Zhao Y, & Chen T (2018) Baseline Hepatitis B Virus Titer Predicts Initial Postpartum Hepatic Flare: A Multicenter Prospective Study.Journal of clinical gastroenterology52(10):902-907.

7. Chen T, Wang J, Qiu H, Yu Q, Yan T, Qi C, Cao F, Tian Z, Guo D, Yao N, Yang Y, He Y, Zhao Y, &Liu Jinfeng(2018) Different interventional criteria for chronic hepatitis B pregnant women with HBeAg(+) or HBeAg(-): Epidemiological data from Shaanxi, China.Medicine97(27):e11406.

8.Liu Jinfeng, Wang J, Jin DF, Qi CJ, Yan TT, Cao FR, Jin L, Tian Z, Guo DD, Yuan NX, Feng WH, Zhang SL, Zhao YR, & Chen TY (2017) Hepatic flare after telbivudine withdrawal and efficacy of postpartum antiviral therapy for pregnancies with chronic hepatitis B virus.Journal of gastroenterology and hepatology32(1):177-183.

9.Liu Jinfeng, Yao N, & Zhao Y (2017) Improvement of telbivudine on renal function and massive proteinuria: A case report.J Viral Hepat24 Suppl 1:75-77.

10.Liu Jinfeng, Chen T, & Zhao Y (2017) Telbivudine therapy for gravidas with chronic hepatitis B infection and patients at risk of renal impairment.J Viral Hepat24 Suppl 1:6-11.

11. Zhang Y, Liu H, Yi R, Yan T, He Y, Zhao Y, &Liu Jinfeng(2016) Hepatitis B virus whole-X and X protein play distinct roles in HBV-related hepatocellular carcinoma progression.Journal of experimental & clinical cancer research : CR35(1):87.

12. Wang J,Liu Jinfeng(共一), Qi C, Yan T, Cao F, Jin L, He Y, Yang Y, Zhang S, Chen T, & Zhao Y (2015) Efficacy of tenofovir disoproxil fumarate to prevent vertical transmission in mothers with lamivudine-resistant HBV.Antiviral therapy20(7):681-687.

13.Liu Jinfeng, Feng YL, Wang J, Li XL, Lei CM, Jin DF, Feng WH, Yang Y, He YL, Li YY, Du D, Zhang XB, Jin L, Yan TT, Chen TY, & Zhao YR (2015) An "immune barrier" is formed in the placenta by hepatitis B immunoglobulin to protect the fetus from hepatitis B virus infection from the mother.Hum Vacc Immunother11(8):2068-2076.12.

国际国内学术会议发言及国际会议摘要:

1.张蒙蒙付珊陈天艳赵英仁刘锦锋(通讯作者);妊娠期干扰素暴露后孕妇和胎儿安全性的系统评价和meta分析;中华医学会第十六次全国感染病学暨第二届国际感染病高峰论坛(2020年北京)大会发言优秀论文一等奖

2.刘锦锋陈天艳赵英仁;HBV母婴阻断证据评估,第三届感染病与肝病卓越研究论坛(2020年上海),青年论坛发言

3.刘锦锋陈天艳赵英仁;HBeAg(-)慢乙肝孕妇母婴传播率远高于HBeAg(+)孕妇;中华医学会第十五次全国感染病学暨国际感染病和临床微生物学学术会议(2018年北京),青年论坛发言

4. Feng, Y.L., Qian, C.L., Yao, N.J., Wu, Y.C., Ma, Y.F., Ma, M.Z., Chen, T.Y., Zhao, Y.R., Chen, Y.L.,Liu Jinfeng(通讯作者), 2019. The Safety of Breast-Feeding on Infant Transmission of Hepatitis B Virus after Combined Immunoprophylaxis: A Systematic Review and Meta-Analysis. Hepatology 70, 598a-599a.摘要

5.Liu Jinfeng, Fu, S., Yao, N.J., Chen, T.Y., Zhao, Y.R., 2019a. The efficacy of two different dosages hepatitis B immunoglobulin in interrupting mother-to-infant transmission of hepatitis B virus: a systematic review and meta-analysis. J Hepatol 70, E124-E124.会议发言

6.Liu Jinfeng, Yao, N.J., Chen, T.Y., Fu, S., Wu, Y.C., Feng, Y.L., Tian, Z., Li, J., Ji, F.P., Chen, Y.L., 2019b. Prevalence of mother-to-child transmission of hepatitis B virus: A systematic review and meta-analysis. J Hepatol 70, E123-E124.会议发言

7.Liu Jinfeng, Wang, J., Guo, D.D., Yan, T.T., Tian, Z., Zhao, Y.R., Chen, T.Y., 2016. Efficacy and safety of Telbivudine or Tenofovir use in second to third trimester preventing vertical transmission of hepatitis B virus in real-life practice. Hepatology 64, 876a-876a.摘要

8.Liu Jinfeng, Wang, J., Jin, D.F., He, Y.L., Jin, L., Yan, T.T., Cao, F.R., Yang, Y., Zhang, S.L., Zhao, Y.R., Chen, T.Y., 2015. Postpartum hepatic flare after telbivudine withdrawal in pregnant women with chronic hepatitis B. Hepatology 62, 998a-998a.摘要

联系方式

联系电话:13259927840

电子邮箱:jinfengliu81@163.com

上一篇:刘昳
下一篇:刘华

地址:陕西省西安市咸宁西路28号 邮编:710049
版权所有:西安交通大学 站点建设与维护: 网络信息中心 陕ICP备06008037号